Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:12 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 14,119 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

NCT07423598
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200
View directory record Official record
Conditions
Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
Interventions
OCE-205, Placebo
Drug
Lead sponsor
Ocelot Bio, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 3, 2026, 5:12 AM EST
Terminated Phase 2 Interventional Results available

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

NCT00784693
View directory record Official record
Conditions
Endometriosis
Interventions
Tanezumab, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Nov 3, 2026, 5:12 AM EST
Terminated Not applicable Interventional Results available

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

NCT01400893
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

NCT03279081
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cx601, Placebo
Drug · Other
Lead sponsor
Tigenix S.A.U.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
68
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional Results available

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

NCT03683719
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Tucson, Arizona • Hialeah, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Nov 3, 2026, 5:12 AM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

NCT01479465
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Nov 3, 2026, 5:12 AM EST
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

NCT03569007
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide, Matching Placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
160
States / cities
Saraland, Alabama • Scottsdale, Arizona • Tucson, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 1 Interventional

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional Results available

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin, Technosphere Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional Results available

rVWF IN PROPHYLAXIS

NCT02973087
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

NCT00174798
View directory record Official record
Conditions
Overactive Bladder
Interventions
SSR240600C, Placebo, Tolterodine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Tuscon, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

NCT00993863
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
aleniglipron or placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Glendale, California • Montclair, California • Valparaiso, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

NCT02635204
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06 Cream, Vehicle Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Glendale, Arizona • Rogers, Arkansas • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 3, 2026, 5:12 AM EST
Terminated Phase 1 Interventional

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

NCT01261767
View directory record Official record
Conditions
Inflammation, Psoriasis
Interventions
anti-IL-20, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Skokie, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

NCT04314544
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
TILD, matching placebo injections
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
Dothan, Alabama • Gilbert, Arizona • Glendale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline, rLP2086, MenACWY-CRM
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

NCT02153099
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-058 (ENV8058), Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

NCT01069809
View directory record Official record
Conditions
HIV Infection
Interventions
AGS-004, Placebo
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

NCT05593432
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Nov 3, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

TD-6450 SAD and MAD in Healthy Subjects

NCT02022306
View directory record Official record
Conditions
Hepatitis C
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Nov 3, 2026, 5:12 AM EST